China's Drugmakers Turn to AI Marketing as Anti-Graft Rules Bite

Pharmaceutical companies in China are exploring marketing through medical AI assistants and disease-specific academic platforms, Reuters reported on November 11, 2026, as a multiyear anti-corruption campaign complicates traditional visits to doctors and hospitals. The shift is already commercial in parts: Null Hypothesis has licensed its KnowS product to major Chinese and foreign drugmakers, while other formats — promoted evidence beside AI answers, preferred search placement — remain proposals.

The stakes are financial and regulatory at once. Stricter enforcement since summer 2026 has raised compliance requirements for pharmaceutical employees who provide product information to doctors and hospitals, pushing companies to redirect promotion budgets toward digital academic marketing built around traceable clinical evidence.

Who is building what?

The emerging opportunity falls into two distinct categories: products already licensed, and ideas still on the table.

• Null Hypothesis's KnowS: CEO Gu Fei said major Chinese and foreign drugmakers have licensed the product to build physician-facing academic platforms focused on particular diseases. He declined to name the licensees.
• Alibaba Health's Hydrion: The company is considering placing promoted research and clinical evidence beside relevant AI-generated answers. It has not begun drugmaker collaborations, although chief technology officer Wang Xiangzhi described interest from domestic and foreign companies as strong.
• Yidu Tech: Drugmakers have discussed search prominence and academic endorsements with the company, which is not yet offering those functions on its Yidu Evidence platform.

Two multinational drugmakers confirmed engagement with the trend. Roche said it explores third-party medical AI tools for direct marketing to doctors and hospitals. Bayer said it monitors technology that could support compliant engagement with healthcare professionals.

Why the Moutai era is ending

Gu described a broader shift away from hospitality and gift-giving toward tools that support clinical work and research. From a doctor's perspective, he said, "this really gives me a new capability and helps me improve efficiency, rather than you giving me two bottles of Moutai."

The quote captures the market logic. Enforcement is not loosening. A campaign against healthcare bribery and corruption intensified in summer 2026, when authorities introduced stricter measures for pharmaceutical employees who provide product information to doctors and hospitals.

Medlive's August 28, 2026 interim results describe sustained enforcement and medical-representative rules as raising compliance requirements. Drugmakers are reducing traditional promotion spending and increasing the budget share for digital academic marketing, according to the same filing.

Adoption data reinforces the direction. Alibaba Health's survey of hundreds of doctors found that 93% used AI tools, compared with about 70% a year earlier. The survey measures AI tools broadly rather than usage of any single platform, but the 23-percentage-point jump in twelve months signals rapid normalization among Chinese physicians.

How large is the market?

Frost & Sullivan estimates that Chinese enterprise spending on digital health marketing will grow at a 27.5% compound annual rate from 2027 to 2030, reaching RMB274.4 billion. The projection covers the broader category and provides no separate figure for physician-facing AI applications.

What do the AI assistants actually do?

The platforms at the center of this story are evidence tools, not chatbots. Their distribution channel is the physician's daily workflow.

Alibaba Health's Hydrion product page describes literature and guideline searches, drug-information lookup, AI question answering, PDF translation and summarization, and content collaborations with BMJ, JAMA and NEJM. Listed resources include:

• 40 million papers
• more than 30,000 guidelines
• more than 60,000 drug instructions

JD Health's Zhiyi, according to the company's September 8, 2026 account, launched in January 2026 and has served more than one million doctors and supported over 20 million clinical decision-making interactions. Its evidence-location feature identifies the original text supporting a clinical point, allowing physicians to trace generated information back to the underlying evidence.

JD Health formed its PICA Health partnership in August 2026, making Zhiyi available free to registered primary-care doctors through PICA's app. PICA Health says AI-embedded content is limited to disease education, clinical guidelines and care standards, excludes branded drug recommendations and product-oriented content, and undergoes academic review.

That policy draws a boundary between clinical education and brand-directed promotion on PICA's platform — even as pharmaceutical companies seek access to the same physician workflow.

Does activity translate into revenue?

Not yet, according to Medlive's numbers. The company's interim results show 217 healthcare customers for precision marketing and corporate solutions in the first half of 2026, up from 191 a year earlier. Marketed products rose from 445 to 509. Segment revenue increased 1.1% to RMB295.5 million.

Medlive attributed the gap between expanding activity and modest revenue growth to two pressures. Stricter regulation disrupted physicians' participation in online and offline academic activities and delayed some projects. Smaller pharmaceutical marketing budgets constrained near-term investment in digital academic marketing.

What happens next?

The picture is split. KnowS licensing and Medlive's customer growth show that parts of the shift are already commercial, while promoted evidence beside AI answers and preferred search placement remain proposals.

The opportunity is tied to a compliance question: how platforms distinguish physician education and traceable clinical evidence from brand-directed promotion as drugmakers seek a larger presence in doctors' daily workflows. Platforms that answer it credibly stand to capture a share of a market projected to reach RMB274.4 billion by 2030.